IBRX vs. CRSP, KRYS, IMVT, HALO, SWTX, EXEL, ACLX, IOVA, APGE, and RVMD
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), Halozyme Therapeutics (HALO), SpringWorks Therapeutics (SWTX), Exelixis (EXEL), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), Apogee Therapeutics (APGE), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics (NASDAQ:CRSP) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 83.4% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CRISPR Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -198,994.05%. CRISPR Therapeutics' return on equity of 0.00% beat ImmunityBio's return on equity.
CRISPR Therapeutics received 457 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 65.43% of users gave CRISPR Therapeutics an outperform vote while only 13.04% of users gave ImmunityBio an outperform vote.
CRISPR Therapeutics has higher revenue and earnings than ImmunityBio. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 19 more articles in the media than ImmunityBio. MarketBeat recorded 21 mentions for CRISPR Therapeutics and 2 mentions for ImmunityBio. CRISPR Therapeutics' average media sentiment score of 0.93 beat ImmunityBio's score of 0.78 indicating that ImmunityBio is being referred to more favorably in the news media.
CRISPR Therapeutics currently has a consensus target price of $73.57, indicating a potential upside of 33.72%. ImmunityBio has a consensus target price of $6.00, indicating a potential downside of 11.76%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than ImmunityBio.
CRISPR Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Summary
CRISPR Therapeutics beats ImmunityBio on 12 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
